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ABSTRACT OF THE THESIS
The Spectral Phasor Approach as a Potential Diagnostic Tool for Breast Cancer
By
Sam Pasin
Master of Sciences in Biomedical Engineering
University of California, Irvine, 2019
Professor Enrico Gratton, Chair
Breast cancer is a significant concern within the United States, causing over 200,000 new
cases and 40,000 deaths each year (1).  A new potential solution in the form of the spectral 
phasor approach to data analysis, paired with the noninvasive imaging approach of DOSI, 
presents itself as a safe, robust, and cost-effective, answering some of the concerns presented by 
current imaging techniques.  By performing a Fourier transform to translate a stack of absorption
coefficients at varying wavelengths to a single value or cluster of points on a spectral phasor 
plot, we are able to visualize the data in a clearly displayed format.  In this paper, we explore the 
spectral phasor approach to analyze data gathered from both a single point on a patient, and 
multiple points in a grid on a patient as means to a diagnosis.  Despite the potential that exists in 
the solution that this approach presents for quick and simple diagnosis, significantly more data is 
required to determine the reliability and reproducibility of this method.
vi
CHAPTER 1 - Introduction
Breast cancer refers to the formation of a malignant tumor in breast tissue.  In the year 
2017, there was an estimated 252,700 new cases of invasive breast cancer and 40,600 breast 
cancer related deaths in the United States [1].  There exists two forms of in situ breast cancer, or 
cancer that is confined to the site that it has originated.  These types of in situ breast cancer are 
identified based on whether it forms in the ducts or the lobules of the breasts [2,3].  Breast cancer
formed in the ducts, ductal carcinoma in situ (DCIS), occurs when abnormal cells replace the 
epithelial cells that line the ducts of the breasts [4].  The other main type of in situ breast cancer, 
lobular carcinoma in situ (LCIS), occurs when abnormal cells forms in the lobules, or milk-
producing glands of the breasts [1,3].  Women with a history either DCIS or LCIS are about ten 
times more likely to develop an invasive breast cancer than women without [5,6].  Most cases of 
breast cancer, about 80%, are
invasive or have spread beyond the
area they have originated.  There are
up to 21 different types of invasive
breast cancer, all of which vary in
terms of cell morphology, growth,
and architecture patterns [7].
As of January 2016, there
were 3.5 million women in the
United States with some history of
breast cancer [8].  According to the
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Figure 1.1: Age-specific Probability of Developing Invasive Breast 
Cancer for US Women
This data table displays how lifetime risk of breast cancer increases 
as a woman ages, and therefore the concern of breast cancer is 
increased in older women.
American Cancer Society. Breast Cancer Facts and Figures 2017-
2018. Atlanta: American Cancer Society, Inc.
American Cancer Society, any 
given woman living in the United 
States has a 12.4%, or about one in 
eight, chance of being diagnosed 
with breast cancer at some point 
during her life [Figure 1.1].  
Incidence rates of breast cancer 
increase with age in women until 
their 60s in which the rates begin to
decrease, possibly to due to lower 
rates of screening and/or 
incomplete detection in older women [Figure 1.2].  Both incidence and death rates of breast 
cancer in non-hispanic white and black women are slightly higher than those of women who are 
native american, hispanic, and asian/pacific islander [Figure 1.3].  In non-hispanic white women 
above the age of 60, the incidence rates of breast cancer are markedly higher than those of other 
demographic groups; however, non-hispanic black women have higher incidence rates before the
age of 40 and are more likely to die from breast cancer at any given age [Figure 1.4].  These 
demographics come as a slight increase over the past four decades are assumed to be due to a 
number of various causes including changes in reproductive patterns, menopausal hormone use, 
rising prevalence of obesity, increased detection through screening, and even longer life 
expectancy [1].
During the 1980s and 1990s, the incidence rates of breast cancer in women rose 
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Figure 1.2: Estimated New Female Breast Cancer Cases and Deaths 
by Age, US, 2017.
The number of new incidences and breast cancer deaths reported 
yearly, and their total percentage.
American Cancer Society. Breast Cancer Facts and Figures 2017-
2018. Atlanta: American Cancer Society, Inc.
drastically [Figure 1.5].  This sudden 
rise is due to the widespread increase 
of mammography screening which 
allowed diagnosis 1 to 3 years earlier 
than without as well as the detection 
of slow growing tumors [1].  
However, some of the increase is 
likely due to changes of reproductive 
patterns that are known to increase 
risk for breast cancer, such as having 
children later and having fewer 
children.  In the late 1980s and early 
1990s, the incidence rates stabilized 
briefly before rising again in the late 
1990s.  This further growth is seen as 
a result of more increases in the 
prevalence in screening, as well as other factors that increase cancer risk, including obesity and 
the use of menopausal hormones.  In the early 2000s, there was a decline of invasive breast 
cancer rates due to a publication that created awareness on the links between menopausal 
hormone use and diseases like breast cancer and heart disease [9].
The American Cancer Society recorded that between the years 1975 and 1989, breast 
cancer deaths steady climbed about 0.4% per year, but since then have dropped to 2015 for a 
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Figure 1.3: Female Breast Cancer Incidence (2010-2014) and 
Mortality (2011-2015) Rates by Race/Ethnicity, US
Breast cancer incidence and death rates of patients of varying 
races/ethnicities.
American Cancer Society. Breast Cancer Facts and Figures 2017-
2018. Atlanta: American Cancer Society, Inc.
total decrease in 39%.  This decrease
occurred in both older and younger
women (though it has slowed in
women younger than 50 starting in
the year 2007), and reveals a total of
322,600 prevented breast cancer
deaths [1].  While not entirely true
for all demographic groups, a
majority of this drop has been
attributed to improvements in
treatment and early detection [10].
Breast cancer survival rates
are an estimation compared to the
average survival rates of people
within the same age and race groups
who are not diagnosed with cancer.
The American Cancer Society’s denotes the average survival rates of patients as the following: 
91% within the first 5 years after diagnosis, 86% at 10 years, and 80% after 15 years [1].  Breast 
cancer survival is strongly determined based on the stage of the cancer after diagnosis, with the 
5-year relative survival rate being 99% for when the cancer is localized in one area, 85% for a 
regional spread of cancer, and 27% for distant-stage cancer [11].  These rates are the average for 
stage of the disease and still vary greatly depending on the size of the tumor, with larger tumors 
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Figure 1.4: Age-specific Female Breast Cancer Incidence Rates by 
Race/Ethnicity, 2010-2014, US
The comparative rates of the incidence of breast cancer between 
patients of varying races.
American Cancer Society. Breast Cancer Facts and Figures 2017-
2018. Atlanta: American Cancer Society, Inc.
greatly lowering survival rates.  This information demonstrates the benefits of early detection of 
breast cancer in keeping survival rates of patients higher.
The most common methods for breast cancer screening including mammography, 
magnetic resonance imaging (MRI),  breast ultrasound, clinical breast examination (CBE), and 
breast self-exams (BSE).  Mammography is a low dose x-ray procedure that allows the 
visualization of the breast in order to diagnose and locate tumors.  This can refer to the following
methods of breast analysis: screen film mammography (SFM), which entails using standard x-
ray equipment to record images, digital mammography (DM), which involves capturing a digital 
image of the breast at lower doses of radiation, and tomosynthesis, where an x-ray source travels 
over an arc capturing thin slices of tissue to minimize the overlapping of breast structures [12]
[13].  SFM has largely been replaced by DM due to the digital method using smaller doses of 
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Figure 1.5: Trends in Incidence Rates of Invasive and In Situ Female Breast Cancer by Age, 1975-2014, US
Relative rates of breast cancer incidences of differing types between women of varying age groups.
American Cancer Society. Breast Cancer Facts and Figures 2017-2018. Atlanta: American Cancer Society, Inc.
radiation as well as being significantly more accurate in women under 50 and in women with 
dense breast tissue [14].  Studies show that the use of breast tomosynthesis in addition to DM can
be used to lower false positives as well as slightly improve cancer detection when compared to 
DM alone.  Unfortunately, the use of tomographic images produces each 2-dimensional image 
separately which causes an increase in the amount of radiation dose a patient will receive from 
diagnosis [13].  For women that are of average risk for breast cancer, the American Cancer 
Society suggests that women who are over the age of 45 should be screened annually for breast 
cancer via mammography and should continue as long as their overall health is considered good 
and they have a life expectancy of over ten years [1].
Despite being the most common clinical means to observe and diagnose cancer, 
mammography suffers from some limitations.  Mammography has been commonly shown to 
produce false-positive results following a women’s initial screening [15].  Starting at age 40, the 
average patient who is screened annually for breast cancer will have a 61.3% chance of being 
called in for additional screening due to false positives within 10 years, and 7-9% will receive a 
false-positive biopsy recommendation [15].  Mammography can result in overdiagnosis of breast
cancer, which refers to diagnoses of cancer that wouldn’t cause a woman harm in her lifetime or 
that would not have progressed in the absence of screening.  These overdiagnoses occur when a 
woman who is diagnosed dies shortly after by another illness, or when there is a non-progressive 
in situ or invasive cancer [1].  Another shortcoming of mammography is the dose of radiation 
that is administered to patients being observed, which very slightly increases risk of fatal breast 
cancer, about 20-25 cases in 100,000 [16].  Despite these limitations, mammography is currently 
considered the most effective method of detecting breast cancer in patients before any physical 
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symptoms manifest.
Magnetic resonance imaging (MRI), is an imaging method involving the use of powerful 
magnetic fields in order to noninvasively examine the human body, can be used for breast 
analysis.  It is performed by injecting a contrast material into the body to capture images of 
breast tissue in high detail and help guide biopsies.  MRI is recommended for use in screening 
women who are at an increased lifetime risk of breast cancer (greater than 25%) beginning at the 
age of 30; conversely, the screening is not recommended for women with a risk of cancer less 
than 15% [17].  Despite this, MRI is more often utilized by people who are low risk than those 
who are high risk [18].  The primary drawback of MRI is the high cost of screening; due to this 
insurance companies only cover a portion of the costs for women who are shown to be high risk 
[1].  Because of this expensive cost of use, MRI screening should only be used in conjunction 
with mammography screening.
Breast ultrasound is a means of observation that uses sound to detect lumps in breast 
tissue.  This means of observation is used in conjunction with mammography and can detect 
cancer more often in patients who are known to have dense breast tissue [19].  A drawback in the
use of ultrasound is that despite leading to an improved detection rate, there is a higher 
likelihood of receiving false-positive results which limits its utility to those with dense breasts 
that require additional visibility [20][21].
Clincal breast examinations (CBE) and breast self-exams (BSE) are similar in that they 
both involve physically feeling for lumps in breast tissue, but CBE is performed by a physician 
during a routine physical and BSE is to be performed by women on themselves about once a 
month.  CBE, when performed in conjunction with a mammography, has had contradicting 
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results ranging from a slight increase to a significant increase in tumor detection when compared 
to mammography alone [22][23].  The American Cancer Society does not recommend the use of 
CBE for average-risk asymptomatic women due to its lack of clear benefits [1].  BSE is also not 
recommended by the American Cancer Society for similar reasons, however it is recommended 
that women become familiar with both appearance and feel of the breasts in order to determine 
and report if any changes have occurred [1][24][25].
Currently the primary as well as most effective means of breast cancer detection, both 
unaccompanied or in conjunction with another method, is mammography.  While mammography
is considered the most effective means of diagnosing breast cancer, there exist issues that this 
method of screening present.  These include issues such as the patient receiving false positive 
diagnoses and doses of radiation that in some cases are enough to form cancer [15][16].  
Mammography also presents the issue of not being fully accepted by some sociocultural 
backgrounds, due to a variety of reasons including fears of embarrassment, pain, cost, and 
potentially hearing negative results [26][27][28].  While many of these concerns are perceived, a 
screening option that is safer for the patient by avoiding concerns of radiation exposure would be
a welcome alternative.  The option of using diffuse optical spectroscopic imaging (DOSI) to 
receive an absorption spectrum in conjunction with spectral phasor analysis approach may offer 
a promising solution to these concerns that mammography presents.
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CHAPTER 2 - Novel Methods
The phasor approach is a method of mathematical analysis thats involves performing 
Fourier transforms to sizeable stacks of data and plotting these on a scatter plot (referred to as the
phasor plot) as a means of creating a simplified representation of the aforementioned data [29].  
When we apply this approach to imaging analysis, it’s most commonly used to evaluate observed
changes over time in a stack of images; this is referred to as temporal phasor analysis and is 
particularly useful in fluorescence lifetime imaging microscopy (FLIM) [30].  More recently, the
phasor method has been found to hold promise in spectral analysis, which we refer to as the 
spectral phasor approach [29].  The scope of this discussion will focus on the latter of these two 
approaches in terms of application in performing analyses.
The spectral phasor approach provides a simple graphical representation of complex data 
sets based on the absorption or emission spectrum of an image.  In this method, a Fourier 
Transform is performed on an image or spectra in order to plot it as a single point on the phasor 
plot [29].  When given a stack of images or a large set of data, the phasor approach allows them 
to be plotted as a cluster of points on 
the plot. Plotting a point on the phasor 
plot is performed in polar coordinates, 
where the angle spanning from the 
origin is referred to as the “phase”, and
the magnitude of the radius is the 
“modulus” [31][Figure 2.1].  The 
phase at which the point lies on the 
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Figure 2.1: Basic Phasor Plot
The modulus (m) and phase (phi) are shown compared to Cartesian 
style (s,g) coordinates.Gratton, E. The Phasor Approach to FLIM 
and FRET. Laboratory for Fluorescence Dynamics
plot is determined by wavelengths of the center of mass of the spectra, whereas the modulus of 
the phasor is based on the average width of the spectrum of each fluorescent component [31].  
When the phasor approach is used to plot fluorescence lifetime or decay, a semicircle 
centered at position g = 0.5 and s = 0 with a radius of 0.5 referred to as the universal circle is 
utilized and the decay is expressed as a point on the chart via transform [32].  In this case, an 
observed lifetime would be plotted on the universal circle curve, therefore a lifetime shifted to 
the right result in a larger phase and decrease in modulus [Figure 2.2 a] In terms of representing 
the spectral phasor, the universal circle is not utilized, and instead the spectra is transformed 
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Figure 2.2: Phasor Transformations
A examples of phasor plots and the transformation equation used when observing fluorescence lifetime (a) and 
spectra (b).
Malacrida L, Gratton E. LAURDAN fluorescence and phasor plots reveal the effects of a H2O2 bolus in NIH-3T3 
fibroblast membranes dynamics and hydration. Free Radical Biology and Medicine. 2018; 128: 144-56.
upon a circle centered at g = 0 and s = 0 with a radius of 1 [32].  In this case, a spectrum with a 
phase shifted more to the right suggests a point on the spectral phasor plot with a large phase 
angle from the origin as well [Figure 2.2 b].  In this way, we can see how positioning of a curve 
affects how it's transcribed onto the phasor plot.
 The spectral phasor method of analysis benefits from being a fit-free approach which, as 
opposed to the use of a global fitting algorithm, the decay of each individual molecular species 
has its own unique representation[31][33].  This representation of raw data takes shape in the 
form of the spectral phasor plot.  Because spectral phasor allows us to easily visualize absorption
spectra as a series of clusters on the phasor plot, this approach has been utilized in visualizing 
biological systems such as lipids or proteins within the cell or on cell membranes [34][35].  
However, there is not a significant amount of data on whether this approach can potentially be 
made use of in diagnostic imaging of tissues in vivo.  When paired with a non-invasive imaging 
technique that provides us an absorption spectrum of tissue, such as diffuse optical spectroscopic
imaging (DOSI), the spectral phasor approach may be able to serve as an analysis method to aid 
healthcare professionals with identification and detection of diseases.  The goal of this is to 
determine spectral phasor viability in performing an analysis on and visualizing breast tissue in a
variety of patients with the purpose of determining whether the approach, when paired with non-
invasive and harmless means of imaging, serves as a viable option for diagnosis of breast cancer.
Our approach to determine the viability to the spectral phasor method requires us to first 
gather light absorption data from breast tissue of varied patients.  Once that data has been 
obtained, the absorption values of chromophores must be analyzed in order to serve as baselines 
for the overall absorption of tissue.  The patient data must then be analyzed via the spectral 
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phasor approach, which entails making use of the Fourier transform to convert the data into a 
single point on the spectral phasor plot.  Once both of these are in place, we are able to compare 
the data of patients with the baseline data the chromophores have given us.  Depending on where
the patient data lies on the spectral phasor plot in relation to that of the chromophores, this will 
allow us to determine whether or not the spectral phasor approach is a feasible means of 
diagnosing breast cancer.
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CHAPTER 3 - Procedure
We begin our approach by receiving data from the Beckman Laser Institute regarding the 
absorption spectra of breast tissue from different points in numerous patients using DOSI.  The 
patients analyzed were all women of varied ages, including groups of patients who were known 
to have tested positively for breast cancer and patients who were cancer free.  DOSI allows us to 
observe individual points on a patient using a broadband lamp (~650-1000 nm) and determine 
the absorbance and reflectance values of these points at various points on the visible light 
spectrum.  DOSI provides high spectral resolution in the data with a low spatial resolution of 
functional quantities using a handheld probe and portable interface [36].  The high spectral 
resolution of DOSI allows us to examine a single point on the breast and find differences in the 
absorption spectra by nanometer of wavelength; this allows us to observe very subtle changes in 
the absorption.  
Before we can analyze this patient data via the spectral phasor approach, we must first 
observe the absorption spectra of the four most
common absorbers of visible light (600 - 1000nm)
in tissue: water, oxygenated hemoglobin,
deoxygenated hemoglobin, and lipid [37].  Each of
these chromophores absorbs one section of the
visible light spectrum more readily than the other
chromophores [Figure 3.1].  The purpose for
determining the absorption spectra of these
chromophores is to create a reference when
13
Figure 3.1: Chromophore Absorption Chart
A graph designating the four primary chromophores 
in tissue, and the wavelengths of light they absorb 
most.
Beckman Laser Institute and Medical Clinic, 
University of California Irvine. Research | DOSI.
analyzing data with the spectral
phasor chart.  These chromophores
all absorb visible light at different
frequencies, therefore performing
spectral phasor analysis on their
respective absorption coefficients
throughout the entire visible light
spectrum creates a single point for
each chromophore on the spectral
phasor chart [Figure 3.2].  When we
have discovered these four points,
the absorption of the light by breast tissue in female patients would also be displayed as 
individual points placed at varied locations on the spectral phasor plot, potentially within the 
region surrounded by the chromophores.  When the breast tissue is examined, the particles in the 
tissue that will absorb light most readily will be these four chromophores.  Depending on the 
composition of the breast tissue in patients analyzed, they should all fall within the region in 
areas closer to the chromophore that they have a higher composition of.  For example, if a patient
has dense breast tissue, which in many cases can be a signifier of a higher probability of breast 
cancer diagnosis, this means that the tissue in that patient is significantly more vascular than that 
of a patient with less dense breasts [38].  In this case, we would assume that the patients with the 
more vascular tissue, and therefore higher concentration of hemoglobin, both oxygenated and 
deoxygenated, will lie closer to where those points are in the spectral phasor plot, as opposed to a
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Figure 3.2: Spectral Phasor Plot with Chromophore Markers
Basic spectral phasor plot, designating where the four primary 
chromophores in tissue lie.
patient with less dense breast
tissue which would therefore have
a higher composition of lipids.
Now that we have a
baseline for various chromophores
on the spectral phasor plot, we
must analyze patient data and
determine where the
corresponding points lie on the
plot.  Using the absorption data for
patients, we perform the Fourier
transforms to convert the data into
points on a phasor plot using an
application called SimFCS.  SimFCS is a software application that was designed for fluorescence
image analysis, visualization, simulation, and acquisition [39].  One of many functions of this 
program is to help simplify the process of calculating the Fourier transform of inputted data.  The
program can perform these calculations on hundreds of wavelengths and their corresponding 
absorption spectra simultaneously, which results in a single point location on the spectral phasor 
plot per absoroption spectra [40].  By performing this task, SimFCS allows us to seamlessly 
convert the absorption coefficients of the patient tissue into points on the spectral phasor plots.  
After performing the analysis on this patient data, we now have a spectral phasor plot containing 
the points that were given from the patient data along with the four points that were gathered 
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Figure 3.3: Spectral Phasor Plot with Markers and Data Points
Spectral phasor plot with data points lying in between the region of the 
chromophores (designated by the encircled points).  All of the 
experimental data points lie within the region, suggesting that they 
represent their proportions of chromophores within their respective 
tissues.
from the chromophore data [Figure 3.3].
Now that we have the spectral phasor plot completed with all the points from patient data,
we can observe the phasor plot to determine whether this method of analysis is viable in 
diagnosis of breast cancer.  We observe that on the plot, all the data points representing patients 
fall within the region where the data points of the chromophores landed.  It is also worth noting 
that the absorption coefficients of each of the patients’ breast tissue do not fall outside of the 
region between the four chromophores.  Because breast tissue should contain some combination 
of the chromophores, the fact that data from all the patients have landed within these four points 
prove that the chromophores within the breast are the only major factors affecting absorption 
coefficient as well as placement on the spectral phasor plot.  This analysis method may serve as a
as a designator to help determine the composition of chromophores within observed tissue, 
which therefore may lead the way to determining a patient’s likelihood of cancer.
While this can give us vague data on a patient’s overall risk of breast cancer, this does not
allow for determining whether certain regions in the breast tissue of a patient contains more 
dense vascular tissue than other points.  However, because the spectral phasor approach allows 
us to perform analysis on large quantities of raw data, we are able to observe breast tissue in 
different regions on a single patient to determine local differences in absorption.  Similarly to our
previous approach, we analyze patients breast tissue with visible light with the goal of gathering 
data on the absorption coefficients at different regions to determine whether tissue contains 
higher concentrations of chromophores over others.
We receive data of the absorption coefficients of patient tissue data observed on multiple 
points in the shape of a  rectangular grid-like pattern on a small area ranging between 4 and 10 
16
centimeters in width and length.  These grid patterns are observed in different areas of breast 
tissue of the selected patient observed.  The absorption data recorded is recorded with broadband 
light once again, for about 700 different wavelengths between 650 and 998 nm, each of these 
wavelengths with a respective absorption coefficient.  We then perform a spectral phasor 
analysis on each of the points on the grids using a program specially developed by Laboratory 
for Fluorescence Dynamics.  Similarly to the approach used in SimFCS, the program performs 
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Figure 3.4: Spectral Analysis Program Results Screen
The results screen of the spectral phasor analysis screen.  We can see the location of the grids analyzed in the 
diagram above, as well as information on the grids on the lower end of the screen.
the function to transform each of the points, but rather than plotting them all on a spectral phasor 
plot, it superimposes a colored grid on an image of a model of a left and right breast.  This allows
for visualization of the tissue composition within each section, which tells us whether or not 
breast tissue has a higher concentration of fatty tissue or vascular tissue [Figure 3.4].
The resulting colored grid previously noted serves as a means of analyzing chromophores
observed within a localized region based on absorption coefficients of those areas.  Each of the 
colors on the grid designates different absorption coefficients of that small region observed.  
Observing the types of chromophores and therefore composition of breast tissue in a small region
allows us to have a clearer idea of whether or not regions are more dense and at a higher risk of 
breast cancer than others, which allows it to be utilized as a diagnostic tool.
18
CHAPTER 4 - Results and Discussion
Our work on the spectral phasor approach and its ability to accurately analyze the 
composition of breast tissue serves as a proof of concept that this method can be used in 
diagnosing a patient’s risk of cancer.  When we analyze the data of multiple patients on a 
spectral phasor plot with the absorption values of the chromophores, we are able to receive 
values within the range of chromophores.  Alongside these findings, the analysis of breast tissue 
from a single patient allows us a grid of varying values based on absorption of the tissue of that 
patient.  Both of these results can be used in conjunction to determine whether or not a patient is 
at a significant risk of cancer.
When we analyzed the absorption coefficient of many patients with the spectral phasor 
approach, we are able to compare the location of patient data with that of chromophores on the 
phasor plot.  Because the observed clusters of patient data on the phasor plots lie between the 
four common chromophores, oxygenated hemoglobin, deoxyhemoglobin, water, and lipids, this 
allows us to understand that this method determines composition of tissue based on location on 
the plot.  The fact that none of these clusters were found outside the region between these 
chromophores is an indicator that the observation of absorption coefficients in this approach is 
not significantly swayed by factors outside of chromophore composition within the tissue.  As 
we have previously made note, the positioning of points or clusters may suggest higher or lower 
concentrations of chromophores when considering their proximity to said chromophore.
The observations made via this test allows us to not only compare the positioning of the 
absorption coefficient to those of the chromophores, but with those of other patients as well.  On 
the spectral phasor chart, the patient data will form clusters depending on what their observed 
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tissues are composed of, which we can
see in [Figure 4.1].  In cases like
these, we may make note of
significant outliers of data that may be
an indicator of unusual concentrations
of chromophores for that given tissue;
cases such as these potentially may be
able to bring physician attention to
abnormalities.  As well as individual
cases of unusual concentrations, this
particular approach may be utilized to
form a database of known dangerous
concentrations in breast tissue.  If patients who are confirmed to be positive for dense or 
cancerous breast tissue have their tissue observed for its absorption coefficient and plotted via 
the spectral phasor approach, it is possible that we may detect a region that may be an indicator 
of high risk of breast cancer.  The utilization of a method such as this may create a highly 
sensitive test, where a preliminary test of absorption coefficient placement on the phasor chart 
could be used to determine whether a patient is high risk for cancer.  In the case that a patient is 
high risk for cancer, this may also be an indicator that the patient will require further testing to 
receive a final diagnosis.
Our next attempt at observing breast tissue composition entailed use of spectral phasor 
analysis on a single patient to determine concentration of chromophores within a small region on
20
Figure 4.1: Phasor Plot with 100 Data Points
All the data points located on the phasor plot fall within a specific 
range, designating similarity in composition.  It is unknown 
whether or not any patients analyzed are in healthy conditions or 
not.
the breast.  As the program performs analysis on a given region’s data and calculates the relative 
absorption of the region in wavelength and compares the absorption on light to specific 
chromophores [Figure 4.2].  This data allows us to observe whether or not the absorption of light
via vascular chromophores is abnormally high, which may be an indicator of an increased risk of
cancer.  The resulting data also gives us a series of grids for each set of patient data, each with a 
heat map designating the absorption coefficient of each area in the grid and therefore tissue 
composition [Figure 4.3].  The figure reveals that areas that have varied compositions show 
significant color change on the grids, and would therefore be slightly more indicative of the 
possibility of a positive diagnosis.  Because of the nature of this analysis of multiple smaller 
regions on a single patient, we are able to more thoroughly analyze tissue in order to develop a 
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Figure 4.2: Spectral Phasor Program Analysis
A section of the main screen of the spectral phasor program.  On the top, we see the proportions of the various 
chromophores and their colors as designated on the chart on the bottom right, which allows us to determine if 
breast tissue is primarily fatty or vascular. On the lower left, we have the relative total absorption over changing 
wavelengths.
highly sensitive and specific 
diagnostic tool.
Each of the methods we’ve 
approached using the spectral phasor 
serve a purpose for observing tissue 
composition and, as a result, serving 
as a diagnostic tool for patients.  
However, it may be possible to use 
tests in conjunction with each other in
order to more adequately perform 
analysis on patients.  The use of 
spectral phasor for absorption values 
on a single location on breast tissue 
allows for a rapid and highly specific 
test that can be plotted on the phasor 
plot alongside data points for 
chromophore absorption and known 
points designating high and low 
cancer risk.  The data placement on that patient can help determine the likelihood of a patient to 
be at risk for cancer.  Following up with patients who appear to have a higher risk of cancer 
would consist of observing various regions of breast tissue and receiving resulting absorption 
coefficients in multiple regions.  When analyzed, we can find more localized areas of dense, 
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Figure 4.3: Spectral Analysis Program Resulting Grids
One of the results screens of the spectral analysis program.  When 
multiple data sets are inputted, multiple grids are given out.  Most 
breast tissue appears uniform when analyzed, though in situations 
where colors in the grid do not appear uniform, as in the bottom 
right, more observation may be warranted.
vascular tissue with the resulting grids of tissue composition.  Additionally, both of these 
methods of analysis have the benefits of being non-invasive and harmless, as well as requiring 
minimal time and effort to perform given basic instructions with simple interfaces.
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CHAPTER 5 - Conclusions
Using spectral phasor, coupled with noninvasive imaging methods such as DOSI, as a 
means of diagnosing breast cancer may serve as a significant improvement when compared to 
current methods.  Contrasting to mammography, the most commonly performed and reliable 
means of performing a breast cancer screening, this method of diagnosis reduces exposure to 
radiation, is cost-effective, and bypasses many of the perceived issues.  We’ve determined a 
process by which the spectral phasor approach can serve as an examination tool when compared  
to numerous absorption values to observe whether or not patients fall within a range of generally 
healthy values or one where a patient should be met with for continued testing.  In conjunction 
with that approach, we’ve detailed the ability to look at absorption values in various points 
across a small region in a breast to determine whether or not there are localized differences in 
tissue composition.
While the spectral phasor approach in conjunction with DOSI imagery has potential as a 
means of observation and diagnosis for breast cancer, continual refining is necessary in order to 
prove the approach’s reliability.  In order to determine values that are more closely identified to 
healthy patients and patients who are suffering from cancer, we require statistically significant 
sample sizes for each of these populations.  As was briefly touched upon previously, our next 
steps in displaying the validity of this approach is to gather this data from numerous patients so 
one we have these values to create ranges on the spectral phasor plane that would be considered 
high risk, as well those of patients who are low risk.  This requires performing DOSI imaging on 
numerous patients and gathering both singular and multiple readings over the grid area.  When 
values can be predictably reproduced, the reliability of this method to make quick and accurate 
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diagnoses will be proven.
In addition to its potential in 
diagnosing breast cancer in patients, 
spectral phasor may have promise in 
observation of other body functions and 
issues. Because of its functionality of 
analyzing copious amounts of data, which 
can also help with determining tissue 
composition, the possibility of observing 
tissue oxygenation in muscles exists as 
well.  The cost-effectiveness and ability to 
quickly analyze multiple points of data 
makes spectral phasor an apt method of 
determining body composition in various 
points, as can be seen in [Figure 5.1].  In 
the figure, ten different body parts are 
analyzed in terms of their composition, 
and where the points lie in relation to the 
chromophores can reveal the body parts’ 
relative level of tissue oxygenation (where
they lie in relation to oxygenated or 
deoxygenated hemoglobin) or fat content 
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(where they lie in relation to lipids).  This data reveals to us how different regions analyzed in 
the same body parts have clusters that lie in similar areas, while those of differing body parts 
suggesting similar tissue composition for different body parts.  Potentially, we can also 
determine the degree of separation between these similar clusters using multiparametric analysis 
of phasor distribution.  This method of analyzing phasor distribution involves determining a 
spectrum corresponding to each phasor plot using the maximum height of the plots' phasor 
distribution histograms, and then comparing these new spectrums [41].  The resulting 
comparison allows us to determine statistical parameters such as the area under the curve, true 
and false positive rates, sensitivity, and positive prediction rate [41].  Multiparametric analysis 
should therefore also be looked at as a possible approach for comparing breast tissue absorption 
based on resulting phasor plots in order to reliably determine composition and create accurate 
diagnoses.
There is significant potential for the spectral phasor approach in terms of analysis of non-
invasive imaging or observation methods.  Despite the continued effort necessary to create 
certainty of spectral phasor as a means of robust, accurate, and reliable breast cancer diagnostics,
there exists significant promise in its ability to meet these requirements.  In addition, spectral 
analysis paired with noninvasive and safe imaging approaches already shows the capability of 
addressing the concerns of the current most prominent methods of analysis.  We have shown the 
spectral phasor approach shows promise and therefore requires continued development to meet 
the standards set before it.
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